Overview

A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients

Status:
Active, not recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

c-TRAK TN is a multi-centre phase II study, consisting of a circulating tumour DNA (ctDNA) screening component and a therapeutic component. c-TRAK TN aims to assess whether ctDNA screening can be used to detect residual disease following patients standard primary treatment for triple negative breast cancer, and will assess the safety and activity of the investigational medicinal product pembrolizumab.

Phase:

Phase 2

Details

Lead Sponsor:

Institute of Cancer Research, United Kingdom

Collaborators:

Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Ltd
National Institute for Health Research Biomedical Research Centre at the Royal Marsden / Institute of Cancer Research UK

Treatments:

Pembrolizumab